BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36917130)

  • 1. Oñate G, Bataller A, Garrido A, et al; CETLAM (Spanish Cooperative Group for the Diagnosis and Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes). Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Adv. 2022;6(3):882-890.
    Blood Adv; 2023 Mar; 7(5):875. PubMed ID: 36917130
    [No Abstract]   [Full Text] [Related]  

  • 2. DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.
    El Ghannam D; Taalab MM; Ghazy HF; Eneen AF
    Blood Cells Mol Dis; 2014; 53(1-2):61-6. PubMed ID: 24512939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
    Forghieri F; Paolini A; Morselli M; Bigliardi S; Bonacorsi G; Leonardi G; Coluccio V; Maccaferri M; Fantuzzi V; Faglioni L; Colaci E; Soci F; Nasillo V; Messerotti A; Arletti L; Pioli V; Zucchini P; Quadrelli C; Corradini G; Giacobbi F; Vallerini D; Riva G; Barozzi P; Lagreca I; Marasca R; Narni F; Mecucci C; Ottaviani E; Martinelli G; Falini B; Luppi M; Potenza L
    Leuk Lymphoma; 2015; 56(11):3222-6. PubMed ID: 25813079
    [No Abstract]   [Full Text] [Related]  

  • 4. Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations.
    West AH; Godley LA; Churpek JE
    Ann N Y Acad Sci; 2014 Mar; 1310(1):111-8. PubMed ID: 24467820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
    Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
    Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status.
    Díaz-Beyá M; Rozman M; Pratcorona M; Torrebadell M; Camós M; Aguilar JL; Esteve J
    Blood; 2010 Dec; 116(26):6147-8. PubMed ID: 21183700
    [No Abstract]   [Full Text] [Related]  

  • 7. NPM1 Biology in Myeloid Neoplasia.
    Patel SS; Kluk MJ; Weinberg OK
    Curr Hematol Malig Rep; 2020 Aug; 15(4):350-359. PubMed ID: 32494951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
    Rogers HJ; Vardiman JW; Anastasi J; Raca G; Savage NM; Cherry AM; Arber D; Moore E; Morrissette JJ; Bagg A; Liu YC; Mathew S; Orazi A; Lin P; Wang SA; Bueso-Ramos CE; Foucar K; Hasserjian RP; Tiu RV; Karafa M; Hsi ED
    Haematologica; 2014 May; 99(5):821-9. PubMed ID: 24463215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1.
    Oñate G; Bataller A; Garrido A; Hoyos M; Arnan M; Vives S; Coll R; Tormo M; Sampol A; Escoda L; Salamero O; Garcia A; Bargay J; Aljarilla A; Nomdedeu JF; Esteve J; Sierra J; Pratcorona M
    Blood Adv; 2022 Feb; 6(3):882-890. PubMed ID: 34516636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Nardi V; Hasserjian RP
    Surg Pathol Clin; 2016 Mar; 9(1):143-63. PubMed ID: 26940274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Any role for the nucleophosmin (NPM1) gene in myelodysplastic syndromes and acute myeloid leukemia with chromosome 5 abnormalities?
    Falini B
    Leuk Lymphoma; 2007 Nov; 48(11):2093-5. PubMed ID: 17990174
    [No Abstract]   [Full Text] [Related]  

  • 12. NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype.
    Zhang Y; Zhang M; Yang L; Xiao Z
    Leuk Res; 2007 Jan; 31(1):109-11. PubMed ID: 16678898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biological features and outcome of NPM1-mutated acute myeloid leukemia.
    Mannelli F; Ponziani V; Bonetti MI; Bencini S; Cutini I; Gianfaldoni G; Scappini B; Pancani F; Rondelli T; Benelli M; Caporale R; Grazia Gelli AM; Peruzzi B; Longo G; Bosi A
    Exp Hematol; 2015 Oct; 43(10):869-879.e22. PubMed ID: 26101160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
    Lin J; Yao DM; Qian J; Chen Q; Qian W; Li Y; Yang J; Wang CZ; Chai HY; Qian Z; Xiao GF; Xu WR
    PLoS One; 2011; 6(10):e26906. PubMed ID: 22066015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic signatures as prognostic tools in acute myeloid leukemia and myelodysplastic syndromes.
    Christopeit M; Bartholdy B
    Epigenomics; 2014; 6(4):371-4. PubMed ID: 25333846
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with
    Ciurea SO; Chilkulwar A; Saliba RM; Chen J; Rondon G; Patel KP; Khogeer H; Shah AR; Randolph BV; Perez JMR; Popat U; Hosing CM; Bashir Q; Mehta R; Al-Atrash G; Im J; Khouri IF; Kebriaei P; Champlin RE
    Blood; 2018 Jun; 131(26):2989-2992. PubMed ID: 29769261
    [No Abstract]   [Full Text] [Related]  

  • 17. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).
    Falini B; Macijewski K; Weiss T; Bacher U; Schnittger S; Kern W; Kohlmann A; Klein HU; Vignetti M; Piciocchi A; Fazi P; Martelli MP; Vitale A; Pileri S; Miesner M; Santucci A; Haferlach C; Mandelli F; Haferlach T
    Blood; 2010 May; 115(18):3776-86. PubMed ID: 20203266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal/Measurable Residual Disease Monitoring in
    Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How I diagnose and treat NPM1-mutated AML.
    Falini B; Brunetti L; Martelli MP
    Blood; 2021 Feb; 137(5):589-599. PubMed ID: 33171486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNMT3A-Mutant Leukemia Cells Primed to "Fork It Over" under DNA Damage.
    Viny AD
    Clin Cancer Res; 2022 Feb; 28(4):573-575. PubMed ID: 34880109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.